Maagensen H, et al. - In this cross-sectional cohort study, researchers examined the influence of the gut on glucose-induced changes in plasma bone turnover markers in healthy controls and patients with type 2 diabetes (T2D) and/or biopsy-verified nonalcoholic fatty liver disease (NAFLD). In patients with NAFLD and T2D, oral glucose tolerance test (OGTT)-induced collagen type 1 C-telopeptide (CTX) suppression appeared to be impaired, however, it was preserved in patients with either NAFLD or T2D. Results of this study suggested that coexistence of T2D and NAFLD could affect gut–bone axis.

Methods

• Study participants were patients with NAFLD with normal glucose tolerance, patients with NAFLD and T2D, patients with T2D without liver disease, and healthy controls.
• CTX, osteocalcin, procollagen type 1 N-terminal propeptide (P1NP), and parathyroid hormone were the main outcome measures.

Results

• According to the findings obtained, plasma glucose levels achieved during OGTTs were successfully matched on corresponding IIGI days.
• They reported that subjects with NAFLD and T2D showed similar CTX suppression during the two glucose challenges (P=0.46) and pronounced suppression of P1NP during IIGI compared with OGTT.
• Remaining groups demonstrated greater (P < 0.05) CTX suppression during OGTT and similar suppression of bone formation markers during IIGI and OGTT.